Federal Government Reclassifies Medicinal Marijuana as Less-Dangerous Drug
The federal reclassification of medical marijuana from Schedule I to Schedule III removes significant research barriers. This change enables clinicians and researchers to conduct more rigorous studies on cannabis efficacy and safety. It also improves…
Results from COSMOS Trial Reveal Cannabis Use in Older Adults
The COSMOS trial reveals cannabis use older adults is more common than expected, with over 75% reporting use. This highlights the need for routine screening in geriatric care. Understanding cannabis use older adults helps clinicians manage safety and…
Duquesne University, Terra Pharm Partner for Cannabis Research
The Duquesne University cannabis research partnership with Terra Pharm marks a significant step in advancing clinical cannabis studies. This collaboration highlights the importance of academic-industry partnerships in generating rigorous evidence. Such…
Adriana E. Ramírez: Trump Administration’s Impact on Cannabis Scheduling
The 2026 cannabis federal scheduling changes directly influence medical access and research opportunities. These policy shifts under the Trump administration affect physician recommendations and patient care. Understanding 2026 cannabis federal…
Trump Administration Advances Marijuana Rescheduling | Brownstein
The Trump administration marijuana rescheduling effort marks a pivotal shift in federal cannabis policy. This change could enable more standardized research and insurance coverage. Clinicians should monitor these developments closely for their impact on…
Trump’s Psychedelic Executive Order: Symbolic Impact Analyzed
The psychedelic executive order impact is largely symbolic but influences research funding and regulatory pathways. Analysts note limited immediate regulatory changes, yet the order signals federal support for psychedelic medicine research. This policy…
Village Farms Opens Groningen Facility to Quintuple Dutch Cannabis Output
The large scale cannabis production facility in Groningen represents a major increase in Dutch medical cannabis output. This pharmaceutical-grade cultivation aims to improve product consistency and supply reliability. Patients may benefit from more…
Confusion Over Federal Medical Marijuana Rescheduling in Colorado
Federal medical marijuana rescheduling confusion is causing regulatory challenges in Colorado. This confusion impacts patient access and continuity of care. Clinicians must understand how these changes affect medical cannabis recommendations.
United States Cannabis Market Set for Explosive Growth Through 2034 | Trader
The United States cannabis market growth 2034 is projected to be explosive, driven by ongoing legalization and regulatory changes. This growth impacts patient access, product quality, and clinical challenges. Clinicians should monitor these developments…
Why Veterans Advocate for Looser Psychedelic and Cannabis Research Restrictions
Veterans psychedelic cannabis research highlights the need for looser restrictions to advance treatment options. This research focuses on PTSD and treatment-resistant conditions common among veterans. Looser research restrictions could enable better…